Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RaniPill containing octreotide · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RaniPill capsule containing octreotide | COMBINATION_PRODUCT | Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule. |
RaniPill containing octreotide is an investigational oral drug delivery platform being developed by Rani Therapeutics Holdings, Inc. (RANI). It is designed to deliver octreotide, a small molecule, through the gastrointestinal tract. The drug is currently in Phase 1 clinical development for use in healthy volunteers.
RaniPill containing octreotide is an oral drug delivery platform that contains octreotide, a small molecule. The specific molecular target of octreotide is not disclosed in the available clinical trial information. The platform is designed to enable oral delivery of the drug, which is being studied in healthy volunteers.
RaniPill containing octreotide is developed by Rani Therapeutics Holdings, Inc., a biopharmaceutical company traded under the ticker symbol RANI on the stock exchange. The company is conducting clinical trials to evaluate the oral drug delivery platform in healthy volunteers.
RaniPill containing octreotide is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is being studied in healthy volunteers as part of early clinical research.
RaniPill containing octreotide has one completed Phase 1 clinical trial, identified as NCT03798912, titled 'A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform.' The trial enrolled 62 healthy volunteers and was an uncontrolled, non-randomized, open-label study.
RaniPill containing octreotide is an oral drug delivery platform that contains octreotide as its active pharmaceutical ingredient. It is not the same as standard octreotide formulations, as it utilizes a novel oral delivery mechanism. The drug is being studied in healthy volunteers in a Phase 1 trial.